Compare BEN & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEN | BAX |
|---|---|---|
| Founded | 1947 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 10.2B |
| IPO Year | 2013 | 1994 |
| Metric | BEN | BAX |
|---|---|---|
| Price | $25.32 | $17.44 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 9 |
| Target Price | ★ $25.89 | $22.38 |
| AVG Volume (30 Days) | 4.5M | ★ 9.4M |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.03% | 0.23% |
| EPS Growth | ★ 7.06 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | $5,774,500,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | N/A | $1.90 |
| Revenue Next Year | $5.76 | $2.09 |
| P/E Ratio | $56.98 | ★ N/A |
| Revenue Growth | N/A | ★ 5.72 |
| 52 Week Low | $16.25 | $17.40 |
| 52 Week High | $28.32 | $36.57 |
| Indicator | BEN | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.54 | 32.04 |
| Support Level | $24.28 | N/A |
| Resistance Level | $25.52 | $19.31 |
| Average True Range (ATR) | 0.82 | 0.70 |
| MACD | -0.26 | -0.39 |
| Stochastic Oscillator | 24.29 | 7.71 |
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.